Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 17/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366820 | 0.94 | GRPR (0.71) | GRPR | |
| SCHEMBL14364817 | 0.92 | GRPR (0.78) | GRPR | |
| SCHEMBL14364818 | 0.92 | GRPR (0.78) | GRPR | |
| SCHEMBL31592157 | 0.91 | GRPR (0.76) | GRPR | |
| SCHEMBL12914181 | 0.91 | GRPR (0.76) | GRPR | |
| SCHEMBL31738157 | 0.91 | GRPR (0.76) | GRPR | |
| SCHEMBL14390132 | 0.91 | GRPR (0.76) | GRPR | |
| SCHEMBL16314443 | 0.91 | GRPR (0.76) | GRPR | |
| SCHEMBL30798936 | 0.91 | GRPR (0.81) | GRPR | |
| SCHEMBL23482609 | 0.91 | GRPR (0.82) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119392492-A | Graphene temperature-sensitive yarn-dyed gauze fabric | 鲁泰纺织股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2026090438-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | DIRECT BIOLOGICS, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20250148668-A1 | SYSTEMS AND METHODS FOR RESERVOIR HISTORY MATCHING QUALITY ASSESSMENT AND VISUALIZATION | SAUDI ARABIAN OIL COMPANY (SA) | 2025-05-08 | — | — | US | disclosed |
| US-12205201-B2 | Systems and methods for reservoir history matching quality assessment and visualization | SAUDI ARABIAN OIL COMPANY (SA) | 2025-01-21 | — | — | US | disclosed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | disclosed |
| US-20240124540-A1 | IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF | ADVAXIS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240083902-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-03-14 | — | — | US | disclosed |
| US-11911451-B2 | Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers | ImmuLogix Ltd (US) | 2024-02-27 | — | — | US | disclosed |
| US-11897927-B2 | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | ADVAXIS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230085337-A1 | BIOMARKER COMPUTING DEVICE AND BIOMARKER COMPUTING METHOD | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2023-03-16 | — | — | US | disclosed |
| US-20230027592-A1 | Method of Protein Extraction from Cannabis Plant Material | AGRICULTURE VICTORIA SERVICES PTY LTD (AU) | 2023-01-26 | — | — | US | disclosed |
| EP-4066671-A1 | CROSS-BRACED SOLE FOR A SHOE | Bär GmbH (DE) | 2022-10-05 | — | — | EP | disclosed |
| US-11384086-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11279705-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220027616-A1 | SYSTEMS AND METHODS FOR RESERVOIR HISTORY MATCHING QUALITY ASSESSMENT AND VISUALIZATION | SAUDI ARABIAN OIL COMPANY (SA) | 2022-01-27 | — | — | US | disclosed |
| WO-2022020282-A1 | SYSTEMS AND METHODS FOR RESERVOIR HISTORY MATCHING QUALITY ASSESSMENT AND VISUALIZATION | SAUDI ARABIAN OIL COMPANY (SA) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083902-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | GRPR 3558/4885 |
| US-11279705-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | GRPR 3558/4885 |
| US-11384086-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | GRPR 3558/4885 |
| US-20230027592-A1 | Method of Protein Extraction from Cannabis Plant Material | CNR2, CNR1, S100P | GRPR 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.